retatrutide clinical trials latest A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Seeking Differentiation Through a Triple

The formula enhances the secretion of PYY and GLP-1, hormones that naturally signal satiety and delay gastric emptying

GLP-1 agonists facilitate rapid weight loss, averaging 15 to 25% of body weight

Tell your healthcare provider if the side effects of Wegovy are severe or do not go away after your body adjusts to the medicine

The risk-to-benefit ratio is excellent, the results are meaningful, and the compound is forgiving enough that minor dosing variations do not cause problems

In Phase 2 obesity trials, retatrutide produced approximately 24% mean body-weight reduction at 48 weeks at the 12 mg dose the largest weight-loss effect reported for any GLP-1-class compound to date

Patients with certain GLP1R variants may respond optimally to semaglutide, while those with favorable GIPR profiles often excel on tirzepatide